Pepstatin
is shown to be a specific inhibitor of acid proteases. It also inhibits humangastricsin, but the effect is weaker than against humanpepsin. The content of pepsin and gastricsin in gastric juice of stomach ulcer patients is described and the pepstatin which remains in gastric juice collected at 60 minutes after its administration is also determined. These results and those obtained by the direct measurements of the peptic activity of the gastric juice indicate that a sufficient amount of pepstatin to inhibit pepsin remains in the gastric juice 60 minutes after oral administration. The peptic activity of gastric juice is 0~9.8 % of the activity of the gastric juice collected before the administration of pepstatin. A method of testing for peptic activity of gastric juice containing pepstatin is described. Free and bound sialic acid in gastric juice of pylorus-ligated rats treated with pepstatin is determined, and pepstatin was shown to inhibit release of bound sialic acid from the mucous membrane. The activity of pepstatin derivatives are described.
As reported in a previous paper1}, pepstatin obtained from cultured broth of actinomycetes was shown to be a specific inhibitor of acid proteases. It did not inhibit trypsin, chymotrypsin, plasmin, kallikrein, thrombin, thrombokinase and papain, but showed a strong inhibition against pepsin and a strong protective effect against stomach ulcer of pyrolus-ligated rats. It has a low toxicity to mice, rats, rabbits, dogs and monkeys, and the effect on stomach ulcer has been studied clinically.
The structure of pepstatin reported in another previous paper2) is as follows :
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In this paper, the effects of pepstatin on acid proteases are reported in detail. Acid protease of Xylaria sp. was prepared and purified using a slight modification of the method described by Koaze3). These enzymes were dissolved and diluted in 0.001N HC1 immediately before use. Human pepsin and gastricsin were prepared by the method å described by Richmond4'53. Human gastric juice was supplied by Dr. Kasugai and Dr. Ito, Aichi Cancer Center, Nagoya. Substrates: Casein was purified according to the procedure described by Norman6) and a 0.6% casein solution in 0.75% lactic acid was employed as a substrate. Bovine hemoglobin was purchased-from Nutritional Biochemical Co., U.S.A., and a 0.5 % hemoglobin solution in 0.03N HC1was used for the experiment. N-Acetyl-L-phenylalanyl-Ldiiodotyrosine (APDT) was purchased from Sigma Chemical Co., U. S. A., and acetyl-Lphenylalanyl-L-tyrosine (APT) was obtained from hemoglobin solution, 0.8ml of 0.02M KC1-HC1 buffer (pH2.0) and 0.1ml of the same buffer with or without an inhibitor were mixed and incubated for 3 minutes. Then, 0.1 nil of a solution of porcine pepsin (10/ig/ml) or other acid proteases was added. The à"concentration of the other acid proteases used was that which had the same activity as 10jugIml of porcine pepsin. After incubation at 37°C for 25 minutes, 2.0ml of 1.7m perchloric acid was added and the mixture kept for 1 hour at room temperature. It was then centrifuged and the extinction of the acid soluble fraction was read at 280 mju. Reaction system for hydrolysis of casein by acid proteases: One ml of 0.6% casein solution, 0.8ml of 0.02m KC1-HC1buffer (pH2.0) and 0.1ml of the same buffer with or without an inhibitor were mixed and incubated for 3 minutes. Then, 0.1 ml of a solution à"of porcine pepsin (40 jug/ml) or other acid proteases was added. The concentration of acid proteases in the solutions was 4 times higher than that used for the hydrolysis of hemoglobin. After incubation at 37°C for 30 minutes, 2.0 ml of 1.7m perchloric acid was added and the extinction at 280 m// measured as described above.
Materials and Methods
Reaction system for hydrolysis of synthetic dipeptide substrate by pepsin : In pepsincatalyzed hydrolysis of APTthe incubation mixture contained 0.25 ml of 10~2MAPT in à"0.065 % Na2CO3, 0.2 ml of 0.05m sodium acetate buffer (pH4.0) with or without an inhibitor and 0.05ml of pepsin solution containing 50jug in 0.001N HC1. After incubation at 37°C for 22 hours, 0.1ml of the incubation mixture was mixed with 0.9ml of 0. .gastricsin from human gastric juice was carried out according to the procedure described by Richmond4>5). One half to one ml of gastric juice from each individual was filtered, dialyzed against 0.2 M sodium citrate buffer (pH 3.0) to remove dialyzable ninhydrin-positive materials and then subjected to ion-exchange column chromatographywith Amberlite CG-50. A column of 0.4x5cm was prepared and equilibrated with 0.2m sodium citrate NO. 1O THE JOURNAL OF ANTIBIOTICS 689 buffer (pH 3.0). After passing the gastric juice through the column, the pH of eluting buffer was changed to 3.7, 4.16 and 4.4 successively and the eluate was assayed for proteolytic activity using hemoglobin as the substrate. The amounts of pepsin and gastricsin separated were calculated from their specific activities in the hemoglobin digestion method. Quantitative determination of gastricsin and pepsin in a mixture of the two enzymes was carried out according to the method of Chiang et aZ.9>10) The total proteolytic activity in human gastric juice was determined by the hemoglobin hydrolysis method and the quantity of humanpepsin in the mixture was determined using APDTas a specific substrate for pepsin since it is not hydrolyzed by gastricsin.
The difference between the total proteolytic activity using hemoglobin substrate and that using APDTas the substrate was taken as the activity of gastricsin. The quantities of pepsin and gastricsin in gastric juices were calculated from their specific activity values as described by Chiang et al.9>10)
Determination of proteolytic activity of gastric juice of stomach ulcer patients before and after administration of pepstatin : The gastric juice of stomach ulcer patients was collected before and after pepstatin administration and its proteolytic activity was measured by another method using hemoglobin as the substrate. The hemoglobin hydrolysis method described above was suitable to measure small quantities of acid proteases, but was unsuitable to measure the peptic activity of gastric juice. If the hemoglobin hydrolysis method described above is utilized, then the gastric juice must be diluted approximately 1,000 times.
Dissociation of the enzyme-inhibitor complex in the gastric juice collected after administration of pepstatin would occur at such a high dilution, and the peptic activity shown by highly diluted juice would not be valid in estimating the activity of the undiluted juice. Therefore, the activity of the gastric juice was determined by the following method. One and one half ml of 2.0% hemoglobin solution adjusted to pH 2.0 with HC1, 0.2ml of 0.02m KC1-HC1 buffer (pH2.0) and 0.3ml of human gastric juice were mixed. After incubation at 37°C for 3 minutes, 2.0ml of 1.7m perchloric acid were added and the extinction at 280 rn/z was measured as described above. The percent inhibition was estimated as described below. Determination of free and bound siali'c acid in gastric juice of pylorus-ligated rats (Shay rats):
Sialic acid in the gastric juice of pylorus-ligated rats with or without the administration of pepstatin was measured by the thiobarbituric method (TBA) of Aminoff115. Crystalline N-acetyl neuraminic acid (NANA) was used as a reference standard with each assay. Free sialic acid was determined by the TBAmethod directly, and the total sialic acid was determined by the TBAmethod after hydrolysis. The bound sialic acid was obtained from the difference between the total and free sialic acid. Four tenth ml of 0.125n H2SO4was added to 0.1 ml of gastric juice and the contents were then hydrolyzed Xylana sj>. Hemoglobin 4.OXIO-7 One reason is thought to be the higher concentration of the enzyme used in the casein system than in the hemoglobin system. It should be noted that the 50%inhibition concentration against the protease of Xylaria sp. is higher against casein than against hemoglobin. Moreover, the activity of pepstatin against this protease is weaker than against the other proteases. As will be described later, the activity of pepstatin against this enzymeis similar to gastricsin. The results shown in Table 1 indicate that pepstatin is a specific inhibitor of acid proteases in general with the exception of some of the fungal enzymes, because 3.6x10"4m of pepstatin showed no inhibition against the following systems when tested by the methods described in previous pepers12~U): hydrolysis of i>-toluenesulfonyl-L-arginine methyl ester hydrochloride by thrombin, fibrinogen by plasmin, casein by trypsin, a-N-benzoyl-Larginine ethyl ester by kallikrein, casein by (2-chymotrypsin, casein by papain, and plasma by thrombokinase. Pepstatin derivatives were tested for their effects on the hydrolysis of casein by porcine pepsin and the results are described in Table 2 . As shown in Table 2 , the esters of pepstatin are equally or slightly more active than pepstatin, which indicates that the free carboxyl group is not essential for the activity. This is consistent with the effects seen in acid conditions. As reported in another paper, the binding of pepstatin with pepsin can be shown using Sephadex G-50 column chromatography of Table 2 . A number of them are marketed as pepsin inhibitors for the treatment of peptic ulcer. However, as shown in the table, they are very weak in inhibiting enzyme activity. In the test system against casein, no inhibition even at 250 jugIml was seen with heparin, chondroitin sulfate, carrageenin and sucrose sulfate. They are therefore at least 25,000 times less active than pepstatin. In general, polyanionic compounds exhibit inhibitory activity against various enzymes and thus, sulfate esters of carbohydrate are probably not specific inhihitors of pepsin. It is possible that pepstatin is the first specific inhibitor of acid proteases to be isolated. Phenylbutazone which is known to be an anti-peptic ulcer agent is 7,000 times less active than pepstatin.
The effects of pepstatin on acid proteases of human, porcine and rat origin were compared, and on the basis of the ID50 values pepstatin show the same inhibitroy activity on the proteases of all three species. Human gastric juice contains an acid protease other than pepsin.
Pepsin and gastricsin were prepared from human gastric juice by the method of Richmond4>5), and the effects of pepstatin on these enzymeswere tested using the hemoglobin hydrolysis system. As shown in Fig. 1 , both the pepsin and gastricsin obtained from human gastric juice are inhibited Pepstatin is now being studied clinically for its effect on stomch ulcer. In order to determine a suitable dose, it was necessary to know the contents of pepsin and gastricsin in gastric juice of stomach ulcer patients. Pepsin and gastricsin in gastric juice were determined by the two methods described in "Methods and Materials". Gastric juice from two patients, with stomach ulcers were analyzed by both methods. After chromatographic separation of these enzymes, the pepsin levels were 346 jugIml and 92 jugIml, while gastricsin levels were 62 /ig/ml and 7 juglml respectively. These results were compared with those obtained by another method based on the difference of substrate specificity between pepsin and gastricsin. The contents of pepsin and gastricsin determined by the second method in the two samples of gastric juice described above are as follows: pepsin 471 jug/ml and 111 #g/ml ; grstricsin 94 jug/ml and 18 jug/mh The two methods therefore gave similar results. Using the second method, the contents of pepsin and gastricsin in gastric juice of 9 peptic ulcer patients were determined. As shown in Table 3 , the pepsin concentration was found to be 111---734 jug/ml and gastricsin concentration 181
58jugIml. The ratio of pepsin to gastricsin was 1.5-6.1.
The residual pepstatin content in the gastric juice of the above-mentioned stomach ulcer patients at 60 minutes after the administration of one or two capsules containing 50mgof pepstatin were determined by two methods. One is based on the fact that two Table 4 .
The results of the determination by two methods are fairly similar.
As reported in the next paper15), pepstatin binds with pepsin in an equimolar ratio and the dissociation constant is less than 3x10~9m. Therefore, an equimolar concentration of pepstatin and pepsin shows almost 100 % inhibition. The molecular weight of pestatin is 686 and that of pepsin is approximately 34,500. As shown in Tables 3 and 4, one would expect that the pepstatin concentration in gastric juice at 60 minutes after administration is sufficient to inhibit pepsin activity. Indeed, when the gastric juice before and after administration of pepstatin is assayed using hemoglobin hydrolytic activity, as shown in the last column of Table 4 pepstatin inhibits the proteolytic enzymes in gastric juices almost completely. The peptic activity of the juice collected 60 minutes after the administration of pepstatin is 0~9.8 % of that of the juice collected before the administration. Free sialic acid and bound sialic acid in gastric juice of pylorus-ligated rats (Shay rats) were determined by the thiobarbituric method (TBA) of Aminoff11}. When 0.5 mg/kg of pepstatin is orally administered to Shay rats, the peptic activity in gastric juice is completely inhibited and a marked decrease of bound sialic acid is observed as shown in Table 5 . The decrease of bound sialic acid in the gastric juice of rats treated with pepstatin suggests that the bound sialic acid (sialoglycoprotein) may be released into the gastric juice by the action of an acid protease on the mucous membrane.
The marked decrease of bound sialic acid might be one of the mechanisms whereby pepstatin prevents stomach ulceration in Shay rats. Protein concentration of human gastric juice was measured by the Lowry16) reaction.
The value was lower in juice collected after pepstatin administration. This result suggests that pepstatin inhibits the release of protein (sialoglycoprotein) from the mucous membrane due to pepsin.
These results indicate that pepstatin can be a useful tool for the study of the mechanism of peptic ulcer formation. As reported in a previous paperx), pepstatin has a very low toxicity and more than 90% of orally administered pepstatin is excreted in the feces in 24 hours after administration. It was also shown that intraperitoneal injection of pepstatin inhibited carrageenin edema of rats17).
These results suggest that an enzyme inhibited by à¬94 THE JOURNAL OF ANTIBIOTICS OCT. 1971 pepstatin is one of the factors responsible for the formation of edema. The low toxicity, the effect against carrageenin edema and the strong inhibitory effect against acid proteases are the biological properties of pepstatin so far observed.
